Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

Nature Medicine

Volumn 4, Issue 1, 1998, Pages 43-49

  Agrawal, Babita ^a   Krantz, Mark J ^a   Reddish, Mark A ^a   Longenecker, B Michael ^a  

^a Biomira Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MUCIN;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ARTICLE; CLONAL ANERGY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; T LYMPHOCYTE; TANDEM REPEAT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD28; APOPTOSIS; ASCITIC FLUID; CA-15-3 ANTIGEN; CELLS, CULTURED; CHROMATOGRAPHY, AFFINITY; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MITOMYCIN; OVARIAN NEOPLASMS; T-LYMPHOCYTES;

EID: 0031914321     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0198-043     Document Type: Article

References (38)

1. Hanisch, H.-G. et al. Structure of O-linked polyacrosaminoglycans on human skim milk mucin: A novel type of linearly extended poty-N-acetyl-lactosamine backbones with Gal β (1-4) GIcNAcb (1-6) repeating units. J. Biol. Chem. 264, 872-883 (1989).
2. Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J. & Burchell, J.A. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol Chem. 263, 12820 (1988).
3. Siddiqui, J. et al. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl. Acad. Sci USA 85, 2320 (1988).
4. Parry, G., Beck, J.C., Moss, L., Bartiey, J. & Ojakian, G.K. Determination of apical membrane polarity in mammary epithelial cell cultures: The role of cell-cell, cellsubstraturn, and membrane-cytoskeleton interactions. Exp. Cell Res. 188, 302-311 (1990).
5. Zotter, S., Hageman, P.C., Lossnitzer, A., Mooi, W.J. & Hilgers, J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev. 11, 55-101 (1988).
6. Burchell, J. et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47, 5476-5482 (1987).
7. Bresalier, R.S. et al. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. A Clin. Invest. 87, 1037-1045 (1991).
8. Kobayashi, H., Terao, T. & Kawashima, Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J. Clin. Oncol. 10, 95-101 (1992).
9. Nakamori, S., Ota, D.M., Cleary, K.R., Shirotani, K. & Irimura, T. MUC-1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Castroenterology 106, 353-361 (1994).
10. Berruti, A. et al. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur. J. Cancer. 30A, 2082-2084 (1994).
11. McGuckin, M.A., Walsh, M.D., Hohn, B.C., Ward, B.C. & Wright, R.G. Prognostic significance of MUC-1 epithelial mucin expression in breast cancer. Hum. Pathol. 26, 432-439 (1995).
12. Hilkens, J. et al. Is episialin/MUC-1 involved in breast cancer progression? Cancer left. 90, 27-33 (1995).
13. Fung, P.Y.S. & Longenecker, B.M. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res. 51, 1170-1176 (1991).
14. MacLean, G.D., Reddish, M.A. & Longenecker, B.M. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level following active specific immunotherapy of metastatic adenocarcinoma patients. J. Immunother. 19, 70-78 (1997).
15. + lymphocytes correlate with effects of theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. 42, 303-309 (1996).
16. Regimbald, L.H. et al. The breast cancer mucin MUC1 as a novel adhesion ligand for endothetial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 56, 4244-4249 (1996).
17. Gimmi, C.D. et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med. 2, 1367-1370 (1996).
18. Berd, D. et al. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol. Immunother. 39, 141-149 (1994).
19. Alexander, R.B. et al. Helper T cells infiltrating human renal cell carcinomas have the phenotype of the activated memory-like T lymphocytes. J. Immunother. 17, 39-46 (1995).
20. Coventry, B.J. et al. Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor infiltrating lymphocytes in primary human breast carcinoma. J. Immunol. 156, 3486-3492 (1996).
21. Kurosaka, A. et al. A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAca2 to 6GalNAc, in mucin-type glycoproteins. J. Biol. Chem. 262, 8724-8726 (1988).
22. Tm RIA for the early detection of breast cancer recurrence in patients with stage II and stage III disease. J. Clin. Oncol. 15, 2322-2328 (1997).
23. + TC1 cells: Loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines. J. Exp. Med. 182, 1505-1515 (1995).
24. Luzzati, A.L. et al. Interferon-gamma (IFN-γ) can counteract the in vitro inhibitory effect of an HIV p24 immunosuppressive heptapeptide. Clin. Exp. Immunol 105, 403-408 (1996).
25. Brunner, T. et al. Cell-autonomous Fas (CD95)/Fas-Hgand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441-444 (1995).
26. Barinaga, M. Life-death balance within the cell. Science 274, 724 (1996).
27. Beverly, B., Kang, S-M., Lenardo, M.J. & Schwartz, R.H. Reversal of in vitro T cell anergy by IL-2 stimulation. Int. Immunol. 4, 661-671 (1992).
28. Mayumi, H., Umesue, M. & Nomoto, K. Cyclophosphamide-induced immunological tolerance: An overview. Immunobiology 195(2), 129-139 (1996).
29. Fontenot, J.D., et al. Biophysical characterization of one-, two-, and three- tandem repeats of human mucin (MUC-1) protein core. Cancer Res, 53, 5386-5393 (1993).
30. Bohmig, G.A., Kovarik, J., Holter, W., Pohanka, E. & Zlabinger, C.J. Specific downregulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-l/ICAM-1 in vitro. J. Immunol 152, 3720-3728 (1994).
31. Ding, L. et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36, 9-17 (1992).
32. Apostolopoulos, V., Loveland, B.E., Pietersz, G.A. & McKenzie, I.F.C. CTL in mice immunized with human mucin 1 are MHOrestricted. J. Immunol 155, 5089-5094 (1995).
33. Agrawal, B., Reddish, M.A. & Longenecker, B.M. In vitro induction of MUC-1 peptide-specific type l T lymphocytes and cytotoxic T lymphocytes responses from healthy multiparous donors. J. Immunol. 157, 2089-2095 (1996).
34. Berd, D., Mastrangelo, M.J., Engstrom, P.F., Paul, A. & Maguire, H. Augmentation of the human immune response by cyclophosphamide. Cancer fies, 42, 4862-4866 (1982).
35. - suppressor-inducer T cells. Cancer Res. 48, 1671-1675 (1988).
36. Fung, P.Y.S., Madej, M., Koganty, R. & Longenecker, B.M. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate, Concer Res. 50, 4308-4314 (1990).
37. + T cells isolated from peripheral blood lymphocytes of normal donors, J. Immunol 157, 3229-3234 (1996).
38. Reddish, M., Black, N., Almeida, A., Suresh, M.R. & Longenecker, B.M. Epitope mapping of MAb B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for the human MUC1 gene. J. Tumor Marker Oncol. 7, 19-27 (1992).